NCT03777306Completed
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
Multiple Myeloma (MM) patients are prone to poor quality of life (QoL) as a result of the anxiety and depression they suffer due to a poor understanding of their disease. Improving patient understanding of their illness and addressing issues that induce distress impacts QoL. This prospective, interventional study is designed to see if a structured psycho-educational program called "the myeloma pack intervention" (MPI), implemented in parallel with standard cancer treatment, can improve QoL for patients with MM.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 85 (actual)
- First submitted
- 27 Sept 2018
- Start date
- 27 Nov 2017
- Primary completion date
- 22 Nov 2024
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Multiple myeloma
- NCT number
- NCT03777306
What you commit to
- Study type: Interventional
- Participants enrolled: 85
- From 27 Nov 2017 to the primary completion date, 22 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- MM patients not requiring systemic therapy.
- Malignancies treated with curative intent and with no known active disease present for ≥ 3 (or 5) years before enrollment and felt to be at low risk for recurrence by the treating physician
- Are enrolled in a prior/concurrent MM psycho-educational study
- Other Exclusions:
Other illness
- Have a history of other malignancy within the past \[3 or 5\] years with the exception of:
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
- Adequately treated breast ductal carcinoma in situ without evidence of disease
- Prostatic intraepithelial neoplasia without evidence of prostate cancer
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
Other
- Patients will be ineligible for the program if they are:
- Being treated by end-of-life or comfort care measures only
- MM patients not treated through the UAB MM Clinic Pathway.
- Patients with a diagnosis of MGUS or SMM.
- Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ
- Patients who do not have either SMS texting or email access to receive encouragement messaging will be excluded
Who the study is looking for
- Of age ≥18 years or older.
- Having a diagnosis of MM; newly diagnosed or relapsed/refractory disease
- Undergoing systemic treatment through the UAB MM Clinic Pathway
- Able to provide informed consent to be included in the intervention
- MM patients in a prior/concurrent (non-pyscho/educational intervention), MM study will be eligible to participate
- Have either SMS texting or email access to receive encouragement messages
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.